Slides
Page 1
Investor Presentation : Financial Results - Q1 FY27 August 7 , 2027 + POLYMED
Page 2
This presentation has been prepared by Poly Medicure Limited (the "Company"), content of which was compiled from sources believed to be reliable for informational purposes only and are based on information regarding the Company and the economic, regulatory, market and other conditions as in effect on the date hereof. Subsequent developments may impact the information contained in this presentation, which neither the Company nor its advisors or representatives are under an obligation to update, revise or affirm. Contents in the Presentation do not constitute or form part of an offer or invitation for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract, commitment or investment decision in relation thereto in India, the United States or any other jurisdiction. Prospective and existing investors should make their own evaluation of the Company as the information provided here does not purport to be all inclusive or to contain all of the information a prospective or existing investor may desire. Interested parties shall conduct their own due diligence and investigation on the information, before relying and acting thereon. Company makes no representation or warranty as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation may contain certain "forward looking statements", which are based on certain assumptions and expectations of future events. Actual future performance, outcomes and results may differ materially from those expressed in forward looking statements as a result of a number of risks, uncertainties and assumptions. Though such forward looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. Neither the Company nor any of its advisors or representatives assumes any responsibility to update forward-looking statements or to adapt them to future events or developments. Disclaimer 2
Page 3
Company Overview
Page 4
Polymed at a Glance 2nd Largest Medical Devices Player in India | Largest Exporter of Medical Consumables PRODUCT PORTFOLIO Infusion Therapy Renal Care Cardiology Critical Care Orthopaedic Transfusion Systems 15 Manufacturing Plants Across 5 countries 225+ Medical Devices 125+ Countries 390+ Patents Granted 1000+ Distributors across India & Globally 4 27% 31% 29% 32% 46% 37% FY 2020 FY 2026 India Europe RoW 1,875687 Safety IV Cannula Prefilled Saline Syringe Needle Free Connectors Three Way Stop Cock with Extension Tube Closed Wound Suction Unit Endotracheal Tubes Fistula Cannula GEOGRAPHIC MIX Dialysis Machine Dialyzer Blood Lines Hemodialysis Catheter Peritoneal Dialysis Set Fistula Needle Transducer Protector Nebulizer Mask DES Diagnostics Catheter Hydrophilic Guidewire Peripherally Inserted Central Catheter PTCA Ballon Dilation Catheter SC PICC Ports Safety Huber Needle Arterial Catheter Central Venous Catheters Mini Mid Lines LA Line Umbilical Catheter PTCA Ballon Dilation Catheter NC IVLDEB Xframe AtlasRondoDolphixKnee, Elbow & Wrist Joint Xfix Eba One, Eba2, DT Omero ACD Bag Umbilical Cord BagLeuko Depletion Filter Bag Hemodraw Bedside FilterMultiple Blood Bag Transfer Bag Rising Contributions from Domestic and European Markets Figs in Rs. Crs unless specified
Page 5
Manufacturing, Packaging and Sterilization • 15 plants in 5 countries • Significant investment in backward integration, Automation and sterilization In-House Product R&D • 390+ patents • 30+ new products launches annually • 90+ R&D professionals Strong Quality and Regulatory Capability • 200+ Quality & Regulatory professionals • Product registration in 100+ countries Sales & Marketing • 590+ direct-sales reps in India, US, Italy, and Mexico; • Expanding presence in other key markets Clinical Engagement • 60+ clinical experts; • 4,000+ annual customer engagement programs globally Distribution Network • 1000+ distributors globally; • Supplying across 125+ countries Polymed Flywheel Integrated business model serving customers globally 5
Page 6
Particulars FY20 FY 22 FY 24 FY26 CAGR (20-26) Infusion Therapy 466 555 925 997 14% Renal 26 60 94 187 39% Others 196 308 356 691 23% Total Operating Revenue 687 923 1,376 1,875 18% Particulars FY20 FY 22 FY 24 FY26 CAGR (20-26) India 187 303 418 582 21% Europe 202 294 454 597 20% RoW 299 325 504 696 15% Total Operating Revenue 687 923 1,376 1,875 18% Segmental Revenue Mix Geographical Revenue Mix Diversified Segment and Geographic Mix 68% 53% 4% 10% 28% 37% FY 2020 FY 2026 PORTFOLIO MIX Infusion Therapy Renal Care Others Towards Portfolio Diversification >> Rising contribution from New Segments | Deepening Presence in the Indian Market # basis consolidated financial statements 6 Figs in Rs. Crs unless specified Figs in Rs. Crs unless specified
Page 7
Moving up the value Chain From essential consumables to advanced Medical Technologies Global Leadership 3rd largest IV cannula manufacturer globally First Indian Company to indigenously manufacture dialysis products Focused on products used in ICU, Neonatology and Oncology • Entered cardiology in 2024 • Launched DES in India in 2025 • Initiated a 2000 patient clinical trial in India and Europe in 2025 • Acquired Citieffe • Overtime to create a comprehensive portfolio EXPANDING TAM CREATING LONG- TERM VALUE STRONGER PORTFOLIO GREATER IMPACT 7
Page 8
A 30 years compounding story – Growth Engine Just warming up Proven yesterday. Scaling today. Defining tomorrow. P O L Y M E D 1 . 0 Foundation FY 1996–2020 • IPO 1996 (Rs 55 Lakhs) • Compounding quietly on internal accruals; • Built global leadership in Infusion Therapy P O L Y M E D 2 . 0 Inflection FY 2020–2026 • First Institutional Raise (Rs 1,400 cr) • Multifold capacity expansion; • Incubated new segments such as Cardiology, Critical Care, and Orthopedics P O L Y M E D 3 . 0 Ascent FY 2027 onwards • Unlocking value via organic & inorganic expansion; • Leverage tech for scaling high complexity verticals globally; • Deepen direct customer access • Strong Balance Sheet & Liquidity (Rs ~850 cr cash) 2000 2010 2020 2026 Revenue 137 EBITDA 29 Revenue 687 EBITDA 166 Revenue 1,875 EBITDA 458 Revenue 10 EBITDA 2 8 Figs in Rs. Crs unless specified
Page 9
Polymed 1.0 (1996 to 2020): Foundation Resiliently built a global medical device platform with equity infusion of INR 5.5mn Key Products 3rd Largest IV cannula manufacturer globally 1st Indian company to indigenously manufacture dialysis products IV Cannula Transfer Bag Single Blood BagIV Sets Endotracheal Tubes Urine Collection Bag Extension Lines Disinfecting Cap ~25 years | Dedicated Focus | Bootstrapped From INR 5.5 Mn IPO in 1996 built a globally competent infusion therapy platform Growth Funded by Internal Accruals Manufacturing Footprint 8 Plants 4 Countries Production Capacity ~1.0 Bn Units Annually +63,000 sq m. Total Plant Area Revenue (FY20) ~INR 7.0 Bn Profitability (FY20) ~68% Infusion Therapy ~73% International Business Op. EBITDA EBITDA Margin ~24.1%~INR 1.7 Bn 2003 JV in Assuit, Egypt 2009 Manufacturing Plant in China 2016 R&D Center 2018 Plan1Health AcquisitionKey Events 9
Page 10
Polymed 2.0 (2021 to 2026): Inflection The inflection: capital, capacity, categories, countries — all scaling in parallel From Capital to Compounding Manufacturing Footprint 15 Plants 5 Countries Production Capacity ~1.9 Bn Units Annually +95,000 sq m. Total Plant Area Revenue (FY26) ~INR 18.7 Bn INR 14 Bn Institutional Equity Raised | Portfolio Expansion Growth Capital utilized towards capacity expansion, deeper penetration in Renal & Critical Care, alongside venturing into Cardiology & Orthopedics ~53% Infusion Therapy ~69% International Business ~INR 4.6 Bn ~24.4% Profitability (FY26) Op. EBITDA EBITDA Margin Key Events 2024 2025 20262021 PendraCare & Citieffe Acquisition | Initiated 3 New Plant construction | 2,000 patient trial of DES QIP : INR 4 Bn QIP : INR 10 Bn Medyneo (Brazil) Acquisition | Haridwar Plant operationalization New Products PTCA Balloon Central Venous Catheters DEB Dialysis Machine DES PICC Ports Guiding Catheter Arterial Catheter 10
Page 11
Polymed 3.0 (2027 onwards): Inflection The next chapter isn’t incremental - it’s exponential ! Vision 2030 2.0x Revenue | Industry-leading margins | Globalization of the Business Model Climb the Tech Ladder • Double R&D spend • Globalize high-complexity verticals — cardiology & critical care • Greater focus on clinical led engagement with end-stakeholders Deepen Market Presence • 30+ new products under registration in Europe • Deepen clinical engagement with customers & stakeholders • Import-substitution success into newer India segments • 100+ new sales associates annually USA Market Expansion • 15 approvals obtained, 11–13 more in the pipeline • GPO contracts signed across multiple accounts • Launch new hi-tech launches M&A Integration • Replicate the P1H playbook for PendraCare & Citieffe • Leveraging product and customer strengths • Collaborate R&D & compounding production capabilities Business Expansion • 2 upcoming plants • Infrastructure set for the next 3–5 years of growth • 25–30 new products launches Go- Direct Strategy • Organic & inorganic expansion — Brazil, SEA, Europe • Leverage existing customer relationships • New products registration 11
Page 12
1 WHAT WE ACQUIRED? ▪ Integrated developer & seller of long- term infusion devices, oncology products and an innovative pain- control device; ▪ Specialist in long-term implantables ▪ A ”made in Europe” critical care brand in oncology segment SYNERGIES REALISED 3.2x REVENUE 11.8x EBITDA +970 BPS MARGIN Revenue EBITDA % 3,239 4,829 8,108 10,514 3.7% 3.8% 10.9% 13.4% 0% 10% 20% 0 3000 6000 9000 12000 2020 2022 2024 2025 Euro Thousands Plan1Health WHY WE ACQUIRED? ▪ Entry into Critical Care segment ▪ Access to clinical data and technology ▪ Regulatory & technical advantage in developed markets: ✓ EN ISO 13485:2003 certified; ✓ Products compliant with EU MDR & CE; ✓ ISO Class 7 Clean Room ✓ Many devices classified as Class III Medical Devices ▪ Competent position • Sole approved supplier for one of the largest OEM for Class III implants; • Global distributor network 2 3 How we acted? - 5 repeatable plays Accelerated product launches Leveraged India manufacturing to reduce cost Invested in enhancing direct sales capabilities Widened distribution reach Collaborated on R&D and marketing 12 Since 1995 | Italy | Acquired 100.0% in 2019 | EV ~Euro 4.2 Mn
Page 13
PendraCare Group – Unique Cardiology Catheter Platform Since 2011 | Netherlands | Acquired 90.0% in 2025 | EV : Euro 18.8 Mn 50+ Countries 50+ Distributors 1,150 m² Cleanroom 3,800 m² 3 Leased Facilities 1.5M+ Capacity/year 65+ Employees A Unique & One of the few independent big players in Interventional Cardiology Catheter business. ▪ Long term relationships with leading global OEMs; ▪ Patented product portfolio ▪ Financial Overview (CY2025): -Revenue: ~Euro 8,200 K; -Gross Margin: ~Euro 5,591 K; -EBITDA: ~Euro 84 K ACQUISITION RATIONALE Product registration in 60+ countries including Europe and US ISO 13485 & FDA Approved manufacturing Strong distribution network & relationship with 2 large OEMs Strategic fitment to grow Cardiology biz globally CY 2025 FINANCIAL* GROWTH DRIVERS ✓ Expanding distribution network ✓ New lease signed for consolidating operations (~2,300m²); transition expected in CY 2028 ✓ Identifying new CDMO projects SYNERGIES EXPECTED ✓ Transferring parts of production process to India; ✓ Collaborating on R&D; ✓ Leveraging distribution network ✓ Deepening global penetration in Cardiology 75% 25% Guiding Catheter Diagnostic Catheter Product Mix CY 2025 13
Page 14
Citieffe - Fully integrated supplier of high-quality Trauma Implants Since 1962 | Italy | Acquired 100.0% in 2025 | EV ~Euro 31.0 Mn 30+ Countries 25+ Distributors 45+ Patents 2,100 m² 2 manufacturing facilities 85.0%+ Sales from countries with direct presence 90+ Employees R&D (5+) & KOL (50+) A fully Integrated developer, manufacturer, and distributor in Trauma and Extremity space. ▪ Rank 2 (In Italy & Mexico) with ~12.0%+ market share. ▪ Key Products: Internal/External Fixators, Instruments, Navigation Systems, etc. ▪ Low customer complaint rate of <0.001% ▪ Financial Overview (CY2025): -Revenue: ~Euro 17,701 K; -Gross Margin: ~Euro 12,093 K; -EBITDA: ~Euro 3,150 K ACQUISITION RATIONALE MDR clearance; products registered with FDA US, LATAM, and 25+ countries ISO 9001, ISO 13485 & FDA certified manufacturing Unique navigation software for nailing systems Access to fastest growing Trauma & Extremity (with-in the large Orthopedics) market CY 2025 FINANCIAL* GROWTH DRIVERS ✓ Strategic expansion in US, largest orthopedics market with prices 4-5x of Europe; ✓ Plan to add Plates to the product portfolio, doubling the TAM; ✓ Maximize value from existing product families ✓ Unlock full market penetration potential SYNERGIES EXPECTED ✓ Deeper penetration in US and Europe; ✓ Product portfolio expansion ✓ Collaboration on R&D; ✓ Manufacturing & Procurement cost saving 48.3% 16.9% 34.8% Europe USA RoW Sales Mix CY 2025 14
Page 15
# basis consolidated financial statements Robust Financial Performance Delivering Strong TSR Revenue from operations (INR Cr) 923 1,376 1,875 FY22 FY24 FY26 2.0x Net Worth (INR Cr) 1,087 1,470 3,149 FY22 FY24 FY26 PAT (INR Cr) 147 258 321 0 50 100 150 200 250 300 350 FY22 FY24 FY26 2.2x ~INR 855 Crs. in Cash & Cash Equivalents – Reserve allocated for strategic initiatives 2.9x Gross Profit (INR Cr) 575 893 1,278 FY22 FY24 FY26 2.2x 62.3% 64.9% 68.2% Operating EBITDA (INR Cr) 216 361 458 0 50 100 150 200 250 300 350 400 450 500 FY22 FY24 FY26 2.1x 23.4% 26.2% 24.4% 15.2% 18.0% 16.1% Margin% 15
Page 16
Strong Promoters and Experienced Leadership Team Promoters Experienced Leadership Team Mr. Himanshu Baid (Managing Director) Co-founder of Poly Medicure, Mr. Baid has over 30 years of experience in the medical device industry and has been instrumental in the company’s growth and innovation. He was honored with the EY Entrepreneur of the Year Award, 2024 in the Life Sciences and Healthcare sector. Mr. Rishi Baid (Joint Managing Director) Co-founder of Poly Medicure, Mr. Baid oversees operations and strategic initiatives, contributing significantly to the company’s expansion and product development with an experience of 28 years. Mr. Vishal Baid (Executive Director) Mr. Vishal Baid is responsible for overall Marketing and in charge of Manufacturing activities in Jaipur with an experience of 25 Years. Mr. Jugal Kishore Baid (Non-Executive Director) A founding member, Mr. Baid has played a pivotal role in establishing the company’s foundation and continues to provide strategic guidance with an experience of 56 years. Mr. Alessandro Balboni (Non-Executive Non-Independent Director) Mr. Balboni brings international business experience, particularly in the European healthcare market, enhancing the company’s global perspective with an experience of 23 years. Mr. Pankaj Kumar Gupta (Executive Director) Mr. Pankaj Kumar Gupta is an accomplished and result- driven Operations Leader with over 35 years of experience. Mr. Indranil Mukherjee (CEO – Asia Pacific & India Business) Mr. Indranil Mukherjee brings 30+ years of medical technology experience across critical care, infusion, renal care, and vascular technologies. Former CEO, Translumina; MD, B. Braun India. Mr. Rahul Gautam (President – Strategy & Corporate Development) Mr. Rahul Gautam has 20+ years of experience in Corporate Strategy, M&A and Capital Markets. He has led M&A and fundraising deals exceeding US$8 billion. Mr. Naresh Vijayvergiya (Chief Financial Officer) Mr. Naresh Vijayvergiya is an accomplished finance executive with 22+ years of experience culminating in CFO and President-level roles, driving financial strategy in manufacturing and commodities sector. Mr. Sujit Gupta (Senior Vice President & Head International Business) Mr. Pascal Govi (CEO – Citieffe Group) Mr. Pascal Govi is a global medtech leader with 30+ years of experience, CEO of Citieffe since 2019 driving international growth. Mr. Sander Hartman (CEO – Pendracare) Mr. Sander Hartman is a seasoned medical device executive with 20+ years of global experience, currently serving as CEO of PendraCare International. Associated with Pendracare group since 2012. Mr. Heyward Powe (Vice President, Sales & Business Development – North America) A senior medical device executive with over 27 years of experience in Vascular Access, Oncology, Cardiology, and Surgery. Mr. Sujit Gupta has 26+ years of international sales experience, driving Poly Medicure's global expansion through strategic partnerships, distribution networks, and export growth. 16
Page 17
Mr. Devendra Raj Mehta (Chairman, Non-Executive Non-Independent Director) A seasoned IAS officer and former Chairman of SEBI, Mr. Mehta brings extensive regulatory and governance experience to the board with an experience of 54 years. Mr. Vishal Gupta (Non-Executive Independent Director) Mr. Vishal Gupta is the Managing Director of Ashiana Housing Ltd., known for pioneering senior living and middle-income housing in India with an experience of 25 years. Mr. Vimal Bhandari (Non-Executive Independent Director) An experienced finance professional, Mr. Bhandari provides valuable insights into financial planning and risk management with an experience of 35 years across IL&FS, AEGON N.V & IndoStar Capital Finance Limited. Ms. Sonal Mattoo (Non-Executive Independent Director) Ms. Mattoo specializes in human resources and organizational development, supporting the company’s talent management strategies with an experience of 28 years. Dr. Ambrish Mithal (Non-Executive Independent Director) A renowned endocrinologist, Dr. Mithal provides medical expertise, aligning the company’s products with healthcare needs with an experience of 39 years. Mr. Amit Khosla (Non-Executive Independent Director) With a strong background in law and corporate affairs, Mr. Khosla aids in ensuring compliance and ethical standards with an experience of 24 years. Robust Governance Framework Non-Executive Board 17
Page 18
Awards & Accolades ET Best Healthcare Brands 2024 Top 75 Industrial Innovative Company of the Year 2024 by CII The Next 500 Companies 2023 by Fortune India Top Exporter of Plastic Medical Disposables from India for 10 Years by Plexconcil Hurun India 2024 List of India's 500 Most Valuable Companies Himanshu Baid, MD, Poly Medicure Healthcare Entrepreneur of the Year 2025 by Financial Express Medical Devices Provider of the Year 2025 by Financial Express Bhamashah Award by Govt. of Rajasthan, Education Dept. Excellence in Medical Equipment Innovation by India Health Next Awards Leading Brand in Medical Devices by Elets Mr Himanshu Baid, MD, Poly Medicure, EY Entrepreneur of the Year Award 2024 - Lifesciences & Healthcare Category Innovative Health Technology Provider of the Year by ET Rajasthan Business Awards Himanshu Baid, MD, Poly Medicure, Healthcare Icon/Leader of the Year 2025 by ET Healthcare Awards Best CSR Initiative in Healthcare, Education & Social Welfare Award by Medgate Today Hurun India 2025 List of India's 500 Most Valuable Companies 18
Page 19
SUSTAINABLE DEVELOPMENT Towards our Commitment to a Sustainable World ➢ Annual Health check-up of 28 employees ➢ Achieved ~6x growth in solar power generation compared to Q1 FY 24-25 SOLAR GENERATIONEMPLOYEE WELLBEING ➢ Approx. 70% facilities are certified under ISO 14001:2015 ➢ Reduced Scope 2 emissions by 8% compared to FY 24-25 ➢ Reduced Scope-2 emission approx. 2,281 tCO2* SCOPE 2 EMISSION Life Cycle Assessment & Critical review SIGNED PPA AGREEMENT ASSESMENTS & INSIGHTS ➢ BRSR Report Assessment is in progress ➢ Enabled by greater utilization of solar power and renewable energy PPAs ➢ Sustainability Report in progress ➢ LCA of two products – Ongoing ➢ 9.9 MWp Solar Energy Plant ➢ Generated approx. 3,214 MWh unit ***The reported Solar units are tentative, as the Monthly Energy Account (MEA) from DHBVN has not yet been received and the renewable energy (RE) adjustment is pending ➢ Well-being health assessments for 2,239 workforce ENVIORNMENTAL MANAGEMENT SYSTEM
Page 20
Financial Results & Key Updates – Q1 FY 27
Page 21
Financial Performance Summary Q1 FY27 Figs in Rs. Crs unless specified Margin,% Revenue 384.0 431.1 Q1 FY26 Q1 FY27 Gross Profit 262.0 308.3 Q1 FY26 Q1 FY27 Operating EBITDA1 101.7 120.8 Q1 FY26 Q1 FY27 No of Patents 399 Cash & Cash Equivalents (INR Crs) 854.7 68.2% 71.5% Revenue Gross Profit 68.4% Operating EBITDA1 73.4% 26.7% 24.1% 26.5% 28.0% Standalone Consolidated 403.2 453.1 72.3 Q1 FY26 Q1 FY27 525.4 276.0 385.6 Q1 FY26 Q1 FY27 107.6 126.7 Q1 FY26 Q1 FY27 Acquisition Impact 1Excludes Other Income 21
Page 22
▪ Appointed Mr. Indranil Mukherjee as CEO – India & APAC (Ex. B Braun & Translumina) ▪ Appointed Mr. Renato Rocha as CEO (effective August 2026) of Polymed Brazil (Ex Descarpack, B.Braun & GE Healthcare) ▪ Appointed Abhimanyu Hooda as Head of Renal Business in India (Ex: Nipro, Fresenius and DaVita) ▪ Cumulative stent deployments surpassed ~13K units (July 2026); DEB-Ex-Vivo preclinical data is obtained with encouraging results ▪ PACIFIER- (DES - Clinical Registry of 2000 patients) 840+ Patients enrolled, with full enrollment targeted by end FY27 ▪ Grew cumulative dialysis machine installations to ~1,100 units, reinforcing our market presence Key Business Updates ▪ Consolidated Q1 FY27 revenue growth 30.3% Y-o-Y; Q1 FY27 Domestic revenue growth 16.2% Y-o-Y and International revenue grew by 36.7% Y-o-Y; ▪ Average price increase of ~4-5% across the business in Q1 FY 27 vs Q4 FY 26 ▪ Q1 FY27 Standalone Operating EBITDA at 28.0%, well above the 25%-27% guidance range; Q1 FY27 Consolidated Operating EBITDA margin at 24.1% within the guidance of 23-25% ▪ Adequate liquidity of Rs 854.7 Crs as at 30th June, 2026 Financial Highlights ▪ 6 new products launched in Q1 FY27 across Infusion Therapy and Critical Care ▪ R&D team strength of 90+ across India, Italy and Netherlands Product Launches & R&D ▪ Achieved ~18% reduction in scope 2 emissions compared through increase utilization of solar and renewable energy PPA ▪ Achieved 6x growth in the solar power generationESG ▪ Recently received “Custodian Award for Best CSR Initiative in Healthcare, Education and Social Welfare” by Medgate Today ▪ Poly Medicure awarded “500 Most Valuable Companies List 2025 ” by Hurun India Awards Key Updates 22
Page 23
Financial Performance Analysis
Page 24
Standalone Financial Performance Summary Figs in Rs. Cr. unless specified Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Revenue from Operations 431.1 384.0 12.3% -Domestic 146.0 125.7 16.2% -International 281.8 256.0 10.1% -Other Operating revenue 3.3 2.4 34.6% Cost of Good Sold 122.8 122.1 0.6% Gross Profit 308.3 262.0 17.7% Gross Profit % 71.5% 68.2% 330 bps Employee Benefit Expenses 88.9 69.2 28.5% R&D Expenses 7.9 7.3 8.5% Other Expenses 90.7 83.8 8.2% Total Expenses 187.5 160.3 17.0% Operating EBITDA 120.8 101.7 18.8% EBITDA % 28.0% 26.5% 154 bps Other Income 28.6 41.1 (30.3%) Depreciation 26.5 23.0 15.3% Finance Cost 4.4 2.8 55.8% PBT 118.6 117.1 1.3% Tax 30.5 29.1 4.7% PAT 88.1 87.9 0.2% PAT % 19.2% 20.7% (151 bps) EPS – Basis (Rs) 8.7 8.7 (0.1%) EPS – Diluted (Rs) 8.7 8.7 (0.1%) Re- classification has been done wherever necessary 24
Page 25
Consolidated Financial Performance Summary Re- classification has been done wherever necessary Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Revenue from Operations 525.4 403.2 30.3% Cost of Good Sold 139.7 127.2 9.8% Gross Profit 385.6 276.0 39.7% Gross Profit % 73.4% 68.4% 495 bps Employee Benefit Expenses 126.9 74.4 70.6% R&D Expenses 7.9 7.3 8.3% Other Expenses 125.7 88.0 42.8% Total Expenses 260.5 169.7 53.5% Share of profit of an associate 1.6 1.3 17.3% Operating EBITDA 126.7 107.6 17.7% EBITDA % 24.1% 26.7% (257 bps) Other Income 33.4 41.7 (19.9%) Depreciation 36.3 23.4 55.1% Finance Cost 6.5 3.0 120.4% PBT 117.3 122.9 (4.6%) Tax 32.0 29.9 7.3% PAT 85.3 93.1 (8.4%) PAT % 15.3% 20.9% (566 bps) EPS – Basis (Rs) 8.5 9.2 (7.6%) EPS – Diluted (Rs) 8.5 9.2 (7.6%) Figs in Rs. Cr. unless specified 25
Page 26
Consolidated Sales Performance Analysis Consolidated Organic Particulars Q1 FY 27 Q1 FY 26 YoY Growth % Q1 FY27 YoY Growth % Domestic 146.0 125.7 16.2% 146.0 16.2% International 376.1 275.1 36.7% 303.8 10.4% Other Operating Revenue 3.3 2.4 34.6% 3.3 34.6% Total Operating Revenue 525.4 403.2 30.3% 453.1 12.4% Geographical Revenue Mix India 146.0 125.7 16.2% 146.0 16.2% Europe 187.3 130.3 43.8% 153.1 17.6% RoW 188.8 144.8 30.3% 150.7 4.0% Other Operating Revenue 3.3 2.4 34.6% 3.3 34.6% Total Operating Revenue 525.4 403.2 30.3% 453.1 12.4% 28% 31% 32% 72% 69% 68% Q1 FY27 Q1 FY26 Q1 FY7 (Organic) Domestic Revenue International Revenue Revenue Mix- Domestic & International 28% 31% 32% 36% 33% 34% 36% 36% 34% Q1 FY27 Q1 FY26 Q1 FY27 (Organic) India Europe RoW Geographical Segment Figs in Rs. Cr. unless specified RoW growth (ex-acquisition) was impacted by crisis in Middle East which de-grew by ~32% on a Y-o-Y basis 26
Page 27
Figs in Rs. Crs unless specified Segment Wise Sales Performance Analysis Q1 FY27 Q1 FY26 YoY Growth % Infusion Therapy 259.2 233.3 11.1% Orthopaedics 49.2 - - Renal 43.2 44.9 (3.8%) Cardiology 28.6 2.9 897.0% Others 141.9 119.7 18.5% Export Incentive 3.3 2.4 34.6% Total Operating Revenue 525.4 403.2 30.3% Revenue Mix- Domestic & International* Infusion Therapy ▪ Delivered strong growth in the domestic market led by increasing share of higher value added products and price hikes ▪ Witnessed recovery in international markets despite degrowth in in the Middle Eastern markets by 32% on account of West Asia crisis Orthopaedics ▪ Reflects the consolidation of revenue of Citieffe Renal Business ▪ Renal Business in the domestic market was impacted due to continued pricing pressure from Chinese players; Polymed decided to increase prices to cushion for the impact of RM price increase ▪ Basis an application by Polymed, Govt has initiated an anti-dumping investigation on imports of Dialyzers from China PR and Malaysia Cardiology ▪ The growth was led by the impact of acquisition of Pendracare and scale up of the domestic business ▪ Revenue mix continues to diversify with Infusion therapy now accounting for 50% of the consolidated revenue 27 50% 58% 9% 8% 11%5% 1% 27% 30% Q1 FY27 Q1 FY26 Infusion Therapy Orthopaedics Renal Cardiology Others *Excluding Export Incentive
Page 28
Promoters, 62.42% Mutual Funds, 9.61% FPIs, 5.57% Insurance Companies, 2.99% AIF, 3.48% Any Other, 0.15% Bodies Corporate, 2.73% Individual, 13.05% Top 10 Institutional Shareholders Sr. No Name % Shareholding 1 Quant Mutual Fund 4.6% 2 Lighthouse 2.3% 3 Axis Max Life Insurance 2.1% 4 UTI Asset Management 2.0% 5 WhiteOak Capital 1.5% 6 Vanguard 1.4% 7 Carnelian Asset Advisors 1.3% 8 SBI Mutual Fund 1.2% 10 HSBC Mutual Fund 0.8% 9 Kotak Mahindra Life Insurance 0.7% Shareholding Pattern as on 30th June 2026 28
Page 29
Thank You Thank You For any investor related queries reach us at: Apoorv.Rastogi@polymedicure.com